TMCnet News
Metamark Genetics Names Dr. Peter Maimonis as Senior Vice President and Chief Science OfficerMetamark Genetics, Inc. ("Metamark" or the "Company"), a leader in commercializing high value urologic oncology products, announced today that Peter Maimonis, Ph.D., has joined Metamark's leadership team as Senior Vice President and Chief Science Officer, effective October 7, 2015. "With his accomplished background in the discovery and development of oncology biomarkers, companion diagnostics, and assays, Peter Maimonis will be a true asset to Metamark and our mission to make better patient outcomes possible through access to better information," said Kenneth Weg, Metamark President and CEO. "We're delighted to have Peter on board to further advance Metamark's lead product, ProMark®, as well as continue to grow our comprehensive portfolio of meaningful diagnostic testing services." Dr. Maimonis brings extensive experience in oncology research and development, and specific proficiency in oncology biomarkers in the area of prostate cancer. He has presented at a large number of national and international scientific conferences, and published many peer-reviewed articles and abstracts on cancer biomarkers. Dr. Maimonis has held senior level positions in various areas of research and development at Ciba-Corning (News - Alert), Chiron Diagnostics, Bayer Diagnostics, Decision Biomarkers, and On-Q-ity, and most recently served as Vice President of Biomarker Development at Biothera, working with their novelcancer immunotherapeutic. "Through advanced diagnostic technology and ProMark®, its leading prognostic assay, Metamark delivers substantial value to physicians and their patients facing prostate cancer," stated Dr. Maimonis. "I'm thrilled to join this world-class management and scientific leadership team, and look forward to propelling Metamark's continued quest to effectively change patient outcomes and improve the standard of care." Dr. Maimonis received his B.S. in Biology from MIT (News - Alert) and his Ph.D. in Tumor Immunology from Brown University, and subsequently received his postdoctoral training at Dana Farber Cancer Institute in biomarkers for lung and breast cancer. He was also a Research Fellow at Harvard with a focus in assay development and clinical application through work with clinicians and surgeons in the area of lung cancer.
About ProMark®
About Metamark® For more information please visit the company's website: www.metamarkgenetics.com. Metamark® and ProMark® are registered trademarks of Metamark Genetics, Inc. View source version on businesswire.com: http://www.businesswire.com/news/home/20151008005236/en/ |